Introduction to Phosphodiesterase Inhibitors
Phosphodiesterase (PDE) inhibitors are termed as therapeutic agents that target PDE isoenzymes and prevents the metabolism of the secondary messengers (cyclic adenosine monophosphate, cyclic guanosine monophosphate) and prolonging the biological effect. Theophylline and papaverine are the two broadly used non-selective phosphodiesterase enzyme inhibitors and are widely accepted to treat various diseases such as cardiovascular, respiratory, and erectile dysfunction. Distinct distribution of all the types of isoenzymes has provided possibilities for selective target therapies. The introduction of selective phosphodiesterase enzyme inhibitors leads to a great impact on the medical treatment sector. Phosphodiesterase superfamily is complex, large, contains one of four genes, and represents 11 gene families from phosphodiesterase 1 to phosphodiesterase 11. The enzymes are found in plasma membranes, cytosol, nuclear membranes, endoplasmic reticulum, and the cytoskeleton.
Market Size and Forecast
The global phosphodiesterase inhibitors market is projected to register a significant rise on account of the escalating prevalence of erectile dysfunction by various factors such as hypertension, obesity, testosterone deficiency, diabetes mellitus, and consumption of certain substance abuse and medications can lead to erectile dysfunction. According to the World Health Organization (WHO), about 150 million people have been affected by erectile dysfunction and this is projected to reach 230 million by 2025. It is a common medical condition affecting about 15% of men each year. Moreover, increasing cases of chronic diseases such as stroke, chronic obstructive pulmonary disease, heart diseases, pre-diabetes, and diabetes are estimated to support the development of phosphodiesterase inhibitors. CLICK TO DOWNLOAD SAMPLE REPORT
The global phosphodiesterase inhibitors market is anticipated to record a notable CAGR over the forecast period i.e. 2020-2028. The market is segmented by drug class, type and application, out of which, the erectile dysfunction sub-segment of application segment is anticipated to hold leading shares in the phosphodiesterase inhibitors market on account of various factors, such as growing incidences of diseases such as diabetes mellitus, testosterone deficiency, prostate cancer, obesity, hypertension, hyperlipidemia, and rising consumption of certain medicines and substance abuse can lead to erectile dysfunction. According to the World Health Organization (WHO), the global prevalence of erectile dysfunction is projected to increase from 150 million in 1995 to 320 million men in 2025. Additionally, the oral segment of the type sector is anticipated to witness a modest growth owing to factors such as low cost, and accurate dosage and stability.
Rising Prevalence Of Chronic Disease And Erectile Dysfunction
The phosphodiesterase inhibitors market is estimated to witness robust growth on account of the growing concern for the chronic diseases such as heart disease, stroke, diabetes, and prediabetes amongst individuals worldwide, which is raising the need for the treatment of the diseases. Further, increasing expenditure for the treatment of such chronic diseases is also anticipated to drive the growth of the market. According to the World Health Organization, 17.9 million people die each year from cardiovascular disease, an estimated 31% of all death worldwide. Moreover, escalating the prevalence of erectile dysfunction multiple factors, such as diabetes mellitus, testosterone deficiency, prostate cancer, obesity, hypertension, and hyperlipidemia are estimated to support the development of the global market. Furthermore, rapid urbanization and the inherent lifestyle changes, along with high stress at the workplace are rendering young men more susceptible to erectile dysfunction.
Potent Drug Interaction of Phosphodiesterase Inhibitors
The global phosphodiesterase inhibitors market is anticipated to hampered by factors such as potential drug interactions of PDE inhibitors, side-effects associated with PDE inhibitors, and the launch of generics.
Our in-depth analysis of the phosphodiesterase inhibitors market includes the following segments:
By Drug Class
On the basis of regional analysis, the phosphodiesterase inhibitors market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.
North America is projected to account for the highest share of the phosphodiesterase inhibitors market throughout the forecast period on account of factors such as the presence of large pharmaceutical companies and increasing lifestyle changes are contributing to the phosphodiesterase inhibitors market growth in the region.
The phosphodiesterase inhibitors market is further classified on the basis of region as follows:
Top Featured Companies Dominating the Market
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization